Regenxbio Inc [RGNX] stock is trading at $12.23, up 3.64%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The RGNX shares have gain 9.78% over the last week, with a monthly amount drifted -6.14%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Regenxbio Inc [NASDAQ: RGNX] stock has seen the most recent analyst activity on February 11, 2025, when Goldman downgraded its rating to a Neutral and also revised its price target to $14 from $38. Goldman initiated its recommendation with a Buy and recommended $38 as its price target on June 07, 2024. H.C. Wainwright started tracking with a Buy rating for this stock on March 11, 2024, and assigned it a price target of $36. In a note dated March 08, 2024, RBC Capital Mkts upgraded an Outperform rating on this stock and boosted its target price from $20 to $35.
Regenxbio Inc [RGNX] stock has fluctuated between $5.03 and $13.93 over the past year. Currently, Wall Street analysts expect the stock to reach $30.14 within the next 12 months. Regenxbio Inc [NASDAQ: RGNX] shares were valued at $12.23 at the most recent close of the market. An investor can expect a potential return of 146.44% based on the average RGNX price forecast.
Analyzing the RGNX fundamentals
Regenxbio Inc [NASDAQ:RGNX] reported sales of 161.32M for the trailing twelve months, which represents a growth of 22.88%. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at -0.96%, Pretax Profit Margin comes in at -1.1%, and Net Profit Margin reading is -1.1%. To continue investigating profitability, this company’s Return on Assets is posted at -0.34, Equity is -0.78 and Total Capital is -0.39. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.47.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.86 points at the first support level, and at 11.49 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.55, and for the 2nd resistance point, it is at 12.87.
Ratios To Look Out For
For context, Regenxbio Inc’s Current Ratio is 2.66. In addition, the Quick Ratio stands at 2.66 and the Cash Ratio stands at 0.47. Considering the valuation of this stock, the price to sales ratio is 3.84, the price to book ratio is 3.83.
Transactions by insiders
Recent insider trading involved Simpson Curran, Chief Executive Officer, that happened on Oct 09 ’25 when 20811.0 shares were sold. Director, CURRAN M SIMPSON completed a deal on Oct 09 ’25 to buy 20811.0 shares. Meanwhile, Chief Executive Officer Simpson Curran sold 7624.0 shares on Sep 29 ’25.
